The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase ...

Experts review warning nail features, from inflammatory conditions to tumours, offering practical guidance on diagnosis and ...

The decision is supported by the Phase 3 PROTOSTAR study, where guselkumab demonstrated higher levels of skin clearance vs. placebo at Week 16. 2 Almost one-third of Pso cases begin in childhood, and ...

Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...

BENGALURU: As cold winter weather wrapped Karnataka after many years, the season also came with an unexpected test of ...

A review indicates that probiotic, prebiotic, and synbiotic supplements could be beneficial for skin health, especially for ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

Adam Thomas has opened up about a tearful "reminder" he stumbled upon whilst having a New Year's sort-out. What might seem ...

Previously, he'd described how months of agony and an incorrect diagnosis eventually led to identifying the chronic condition ...